Takeda (TAK) announced the Japanese Ministry of Health, Labour and Welfare has approved the use of ADZYNMA for the treatment of congenital thrombotic thrombocytopenic purpura for individuals 12 years of age and older. The company said the approval does not result in any changes to consolidated forecast for the fiscal year ending March 31, 2024.
"The approval of ADZYNMA is an important milestone for people living with cTTP in Japan, who had limited treatment options and now have the first treatment option specifically approved to treat this ultra-rare condition," said Yasushi Kajii, Head, R&D Japan Region at Takeda.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.